Release Date: 23-Jan-2025
Obrixtamig (BI 764532) is an investigational bispecific antibody developed by Boehringer Ingelheim, designed to treat small cell lung cancer (SCLC) and other neuroendocrine neoplasms expressing the delta-like canonical Notch ligand 3 (DLL3) protein. This novel therapy is a DLL3/CD3 immunoglobulin Gandndash;like T-cell engager that works by redirecting the body’s own T cells to target and destroy cancer cells that express DLL3. The DLL3 protein, which is found at high levels on the surface of tumor cells in SCLC and other neuroendocrine cancers, is a promising target for immune-based therapies. Obrixtamig uses the OGAPandreg; Discovery Platform from Oxford BioTherapeutics to identify and develop such targeted treatments.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
The bispecific design of Obrixtamig allows it to engage both DLL3 on the tumor cells and CD3 on T cells, thereby redirecting T cell-mediated immune responses to the cancer cells. This mechanism is intended to lead to the activation of T cells, which can then attack and eliminate the DLL3-expressing tumor cells. By specifically targeting tumors that express DLL3, Obrixtamig aims to minimize damage to healthy tissue, offering a more precise and effective treatment option for patients with these aggressive cancers.
BI 764532 has shown particular promise in the treatment of relapsed or metastatic SCLC, large-cell neuroendocrine carcinoma of the lung (LCNEC-L), and extra-pulmonary neuroendocrine carcinoma (ep-NEC), which are cancers known for their poor prognosis and limited treatment options. The therapeutic potential of Obrixtamig in these cancers was recognized by the U.S. FDA, which granted it Fast Track designation for advanced or metastatic LCNEC-Lung and extensive-stage SCLC (ES-SCLC) expressing DLL3.
Currently, BI 764532 is undergoing Phase 2 clinical trials to evaluate its safety and efficacy in patients with SCLC and ep-NEC. These trials are exploring its potential to improve outcomes for individuals with these difficult-to-treat cancers, offering hope for a new, more effective approach to treatment. The ongoing studies will provide crucial insights into whether Obrixtamig can become a viable therapeutic option for patients whose cancer has not responded to other treatments.